To the full analysis
Medicover stock: growth
MCOV-B.STMedicover reported $2.64B in revenue for fiscal 2025, up 13.7% on the prior year, up 19% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
18.6%
per year from 2014 to 2025, per share 17.3%
Earnings (Annual rate)
30.1%
per year from 2014 to 2025, per share 28.5%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2014 | |
|---|---|---|---|
| Revenue | 19.0% | 19.1% | 18.6% |
| Revenue per share | 17.5% | 17.6% | 17.3% |
| Earnings | 24.6% | 26.3% | 30.1% |
| Earnings per share | 23.2% | 24.7% | 28.5% |
| Free cash flow | 17.3% | no data | no data |
| Free cash flow per share | 15.9% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2014 | $404.79M | $4.76M | −$2.11M |
| 2015 | $460.53M | $8.31M | −$2.33M |
| 2016 | $551.06M | $4.76M | −$31.47M |
| 2017 | $642.92M | $20.72M | $23.16M |
| 2018 | $744.2M | $27.26M | $3.77M |
| 2019 | $935.68M | $24.93M | $26.71M |
| 2020 | $1.11B | $28.59M | $92.53M |
| 2021 | $1.53B | $112.8M | $126.88M |
| 2022 | $1.67B | $13.08M | $32.8M |
| 2023 | $1.94B | $19.5M | $104.72M |
| 2024 | $2.32B | $18.51M | $154.69M |
| 2025 | $2.64B | $85.88M | $205.66M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729, $1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 27 Jun 2025)
- Valuation signal Overvalued since 8 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.